- Home
- NKTR vs TSI Comparison
NKTR vs TSI Comparison
Compare NKTR & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- TSI
- Stock Information
- Founded
- NKTR 1990
- TSI 1987
- Country
- NKTR United States
- TSI United States
- Employees
- NKTR N/A
- TSI N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- NKTR Health Care
- TSI Finance
- Exchange
- NKTR Nasdaq
- TSI Nasdaq
- Market Cap
- NKTR 238.7M
- TSI 244.7M
- IPO Year
- NKTR 1994
- TSI N/A
- Fundamental
- Price
- NKTR $1.32
- TSI $5.10
- Analyst Decision
- NKTR Buy
- TSI
- Analyst Count
- NKTR 4
- TSI 0
- Target Price
- NKTR $2.50
- TSI N/A
- AVG Volume (30 Days)
- NKTR 1.1M
- TSI 106.8K
- Earning Date
- NKTR 11-05-2024
- TSI 01-01-0001
- Dividend Yield
- NKTR N/A
- TSI 7.46%
- EPS Growth
- NKTR N/A
- TSI N/A
- EPS
- NKTR N/A
- TSI N/A
- Revenue
- NKTR $93,157,000.00
- TSI N/A
- Revenue This Year
- NKTR N/A
- TSI N/A
- Revenue Next Year
- NKTR N/A
- TSI N/A
- P/E Ratio
- NKTR N/A
- TSI N/A
- Revenue Growth
- NKTR 6.17
- TSI N/A
- 52 Week Low
- NKTR $0.41
- TSI $4.48
- 52 Week High
- NKTR $1.93
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- NKTR 54.62
- TSI 51.89
- Support Level
- NKTR $1.24
- TSI $5.05
- Resistance Level
- NKTR $1.42
- TSI $5.10
- Average True Range (ATR)
- NKTR 0.09
- TSI 0.06
- MACD
- NKTR 0.01
- TSI -0.00
- Stochastic Oscillator
- NKTR 67.74
- TSI 59.62
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.